Abstract: Canola protein isolates consisting predominantly of 7S canola proteins are formed by isoelectric precipitation from aqueous salt solution extracts of canola oil seed meal. Canola protein isolates consisting predominantly of 2S canola protein are recovered from supernatant from the isoelectric precipitation step.

Abstract: The present invention relates to compositions (i.e., various organic small molecules as exemplified herein) and methods for the inhibition of protein splicing and especially relates to the inhibition of protein autosplicing of intein-containing proteins. Additionally, the present invention relates to the use of the inhibitors of protein splicing of the invention for the treatment of various diseases including but not limited to tuberculosis. Furthermore, the invention provides the first instance of small molecule inhibitors of protein splicing with drug-like characteristics.

Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Abstract: The present invention relates to a method for the purification of non-immunoglobulin proteins comprising one or more immunoglobulin-like (Ig-like) domain.

Abstract: The present invention relates to a bioadhesive derived from mussel. In particular, it relates to a novel Mytilus galloprovincialis foot protein type 5 (MGFP-5) and a recombinant protein that is a hybrid of MGFP-5 and foot protein type 1 (FP-1), where an adhesive protein with adhesive activity can be economically mass-produced to be used in place of chemical adhesives through the present invention.

Abstract: The present invention discloses a method of producing polypeptides, including insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs, by ligating genes in a tandem way. Also disclosed are the recombinant polypeptides produced by such a method. Using the method of this invention, 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes may be expressed in tandem and the desired polypeptide can be obtained after cleavage of a fusion protein and further processes of separation and purification thus making possible the production of recombinant polypeptides, including recombinant GLP-1 (7-36) and/or GLP-1 analogs on a large scale, at a significantly reduced production cost.

Abstract: The present invention provides a method for specifically recovering a C-terminal peptide fragment, and a method for easily determining the sequence of a C-terminal peptide fragment, which is difficult to be determined by a conventional method, with the use of a mass spectrometer, in particular a method capable of de novo sequencing of a C-terminal peptide fragment. A method for selectively recovering a C-terminal peptide of a protein, comprising the steps of: in a cleavage product of a protein containing a C-terminal peptide fragment (A) having an ?-amino group but not having an ?-amino group and the other peptide fragments (B) having an ?-amino group and an ?-amino group, selectively modifying the ?-amino groups to obtain a C-terminal peptide fragment modified (A?) and the other peptide fragments modified (B?); and separating the C-terminal peptide fragment modified (A?) from the modified cleavage product by allowing a carrier to hold the other peptide fragments modified (B?) via the ?-amino group.

Abstract: The invention is based on the discovery that certain biarsenical molecules react with specified target sequences, thereby providing a facile means for labeling polypeptides containing the target sequence. The invention is useful in creating stable mammalian cell lines expressing a certain tetracysteine tagged polypeptides, thereby overcoming toxicity associated with native tetracysteine. In addition, the invention allows for orthogonal labeling of polypeptides, thereby allowing for the observation of protein-protein interactions and conformational changes in proteins, for example.

Abstract: The present invention relates to a method of detecting the presence, amount or subcellular location of an antigenic structure of interest in a cell, comprising the steps of: (a) (i) expressing a fusion protein directed to the antigenic structure of interest in said cell or (ii) introducing a fusion protein directed to the antigenic structure of interest and coupled to a (poly) peptide capable of transducing into said cell; wherein said fusion protein comprises a first (poly) peptide sequence comprising the variable region of a heavy chain antibody of Camelidae and a second (poly) peptide sequence derivable from a fluorescent or chromophoric protein.

Abstract: The present invention relates to compositions, methods, and uses for isolated biomolecule-containing fibers. The invention also relates to isolated, elongated biopolymers such as nucleic acids, polypeptides, lipids, and carbohydrates within fibers. The invention relates to methods of detecting and analyzing biomolecules in fibers using light, electrons, and neutrons. The invention further relates to methods of determining the sequence, structure, and properties of isolated, elongated biopolymers fixed within fibers.

Abstract: The invention relates to a method with which proteins from formalin-fixed biological samples can be dissolved and subsequently quantified. The method makes it possible to extract intact full-length proteins from the samples and to conduct a subsequent analysis thereof.

Abstract: The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention.

Abstract: Use of modified metal oxides for the purification and enrichment of negatively charged biomolecules such as peptides, proteins, DNA, RNA, Lipids, carbohydrates, glyco molecules. These metal oxides are modified in such a way that the density of the Lewis acid group is reduced due to modification.

Abstract: The use of hydrophobic coated metal oxides particles or film for the purifications of proteins, peptides or other biomolecules. This process eliminates two steps of purification as compared to silica or polymer based particles.

Abstract: The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques.

Abstract: A method is described for releasing a soluble or membrane associated intracellular protein of interest (POI) comprising the steps of: providing a cell comprising a soluble or membrane associated intracellular POI; contacting the cell with a membrane extracting composition; and causing the POI to be released from the cell under conditions sufficient for the specific release of the POI and in a soluble form.

Abstract: The present invention is related to a method of producing a peptide, characterized in contacting a reaction mixture with a base after a condensation reaction to hydrolyze while a basic condition is maintained until a ratio of a remaining unreacted active ester of an acid component is decreased to 1% or less in a liquid phase peptide synthesis method. According to the invention, a target peptide of high purity can be simply and efficiently produced by a continuous liquid phase synthesis method. Further, the present invention is related to a method of producing a peptide, characterized in using an amide-type solvent immiscible with water in a liquid phase peptide synthesis method. According to the invention, various peptides can be produced by the liquid phase synthesis method without being restricted by the amino acid sequence of the target peptide.

Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.

Abstract: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides.

Abstract: The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities.

Abstract: The invention relates to the recombinant expression of a peptide of interest in the form of a fusion protein comprising a solubility tag. The fusion protein comprises at least two portions separated by a cleavable peptide sequence wherein one portion is devoid of cysteine residues and the second portion comprises an effective number of cross-linkable cysteine residues. After cell lysis and isolation of the fusion protein, the fusion protein is subsequently cleaved into a mixture of first and second portions. Oxidative cross-linking is used to selectively precipitate one of the two portions to facilitate simple and effective separation of the peptide of interest.

Abstract: Described herein are methods and techniques to study the “degradome”. The degradome of a specific protease is the complete product of the natural substrate repertoire of that enzyme in a cell, tissue or organism. The complete set of proteases that are expressed at a particular moment or circumstance by a cell, tissue or organism produces the collective degradome. Included in the methods described herein are approaches that allow the direct identification and characterization of degradome peptides from approx. 400 to approx. 12,000 Da. The methods of the invention avoid the inherent problems of studying the peptidome by focusing on specific or unique proteolytic cleavages that occur as a result of endogenous protease activity induced by specific diseases. Once characterized, the presence of, or change in level of, specific peptides of the degradome can be used, e.g.

Abstract: Methods are disclosed for rapid, reliable and simple isolation of RNA from formalin-fixed paraffin-embedded tissue samples. RNA purified in this manner can be used to monitor gene expression levels. The tissue sample can be a tumor or other pathological tissue.

Abstract: A method of sterilising a protein in an aqueous environment, comprises exposing to ionising radiation an aqueous composition comprising the protein with a protective compound or combination of protective compounds having the following characteristics: (i) a rate of reaction with hydroxyl radicals greater than 5×108 L mol?1 s?1; and (ii) a non-polar region.

Abstract: Changes in sialylation of cell surface or plasma proteins are often associated with various cancers and other disease conditions Provided are methods of detecting biomarkers of conditions associated with a change of sialylation status. Sialylated peptides are first isolated from biological and other samples by loading onto titanium dioxide (TiO2) or zirconium dioxide (ZrO2) stationary phase under acidic conditions in a solution comprising at least 20% organic phase and at least about 6.5 mM of substituted aromatic carboxylic acid, or, alternatively, at least about 1 mM short chain, non-aromatic, hydroxylated carboxylic acid. Sialic acid containing proteins can then be eluted from loaded stationary phase material by exposure to an alkaline solution having pH of 9.0 or greater, preferably at least 10.5.

Abstract: This invention relates to a composite material that comprises a support member that has a plurality of pores extending through the support member and, located in the pores of the support member, and filling the pores of the support member, a macroporous cross-linked gel. The invention also relates to a process for preparing the composite material described above, and to its use. The composite material is suitable, for example, for separation of substances, for example by filtration or adsorption, including chromatography, for use as a support in synthesis or for use as a support for cell growth.

Abstract: The subject invention provides a sample processing technique for purifying a biological or chemical sample. The invention is particularly well-suited to prepare a sample for mass spectrometry. The process is to be performed in an article having at least one well, in which the surface of the well is at least partially hydrophobic and/or modified with bio-specific ligands. Targeted solutes, such as salts or small molecule contaminants, can be removed from a solution to allow for a purified solution of a desired type of solute, such as peptides and/or proteins.

Abstract: The present invention provides methods of purifying proteins that include a metal ion affinity peptide. The methods generally involve contacting a fusion protein that includes a metal ion affinity peptide with at least two different metal ion chelating resins. In certain representative embodiments, the methods include contacting a fusion protein with a first metal ion chelate resin having a first immobilized metal ion; eluting any bound protein from the first metal ion chelate resin, to produce an eluate; contacting the eluate with a second metal ion chelate resin having a second immobilized metal ion; and eluting any bound protein from the second metal ion chelate resin. Also provided are kits for use in practicing the subject methods. The subject methods find use in a variety of protein purification applications.

Abstract: Disclosed herein are methods of detecting non-natural amino acids and polypeptides that include at least one non-natural amino acid. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, including but not limited to oxime, carbonyl, and/or hydroxylamine groups. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, and methods for detecting such polypeptides.

Abstract: This invention relates to a method of producing a purified polymer selected from the group consisting of PNAs, (poly)peptides, PNA chimera, peptide-DNA chimera, and derivatives thereof, wherein the polymer carries at least one lipophilic group and wherein the method comprises the following steps: (a) transferring a solution comprising the polymer carrying a lipophilic group to a lipophilic surface under conditions that allow binding of said lipophilic group to said lipophilic surface; (b) washing said surface under conditions that allow said binding to be maintained, wherein polymers not carrying said lipophilic group are removed; (c) washing said surface under conditions that break said binding; (d) collecting the washing solution from step (c); and (e) obtaining said purified polymer from said washing solution. Preferably, the lipophilic group is a protection group, or a label such as a fluorescent dye, or a linker, for example a linker suitable for immobilization on a support.

Abstract: The peptide has a sequence of 3 to 30 adjacent amino acids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. The compositions are suitable for the treatment of facial wrinkles, asymmetry and pathological neuronal exocytosis-mediated pathological disorders and alterations.

Abstract: The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multi-use biomolecule lysate. This method allows for simultaneous extraction, isolation, solublization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments.

Abstract: Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.

Abstract: Provided is a method of separating a peptidoglycan-recognition protein from the hemolymph of Tenebrio molitor larvae, the method including: (a) preparing an affinity chromatography column by packing a column with a resin bound with at least one synthetic peptidoglycan; (b) applying the hemolymph of Tenebrio molitor larvae to the affinity chromatography column; (c) applying a mobile phase to the affinity chromatography column to obtain a peptidoglycan-recognition protein-containing solution eluted from the affinity chromatography column; and (d) purifying a peptidoglycan-recognition protein from the eluted solution.

Abstract: The invention relates to a use of an activated polymer to separate a non-covalently associated polypeptide multimer comprising multiple polypeptide subunits into multiple polypeptide subunits.

Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.

Abstract: Aspects of the present invention relate to compounds for preparing fluorocarbon compounds, methods for preparing fluorocarbon compounds, and methods for purifying a mixture of compounds. One aspect of the present invention relates to a trivalent iodonium fluorocarbon. The trivalent iodonium fluorocarbon compound of the invention is useful for attaching a fluorocarbon group to a compound that has a nucleophilic functional group. Another aspect of the present invention relates to a method of preparing a trivalent iodonium fluorocarbon. Another aspect of the present invention relates to a method of preparing a fluorocarbon by treating a compound bearing a nucleophilic functional group with a trivalent iodonium fluorocarbon compound.

Abstract: The invention provides methods for detecting and isolating phosphomolecules using phosphoaffinity materials that comprise a hydrated metal oxide. In an embodiment, a method for detecting a phosphomolecule in a sample involves (a) contacting a sample with a phosphoaffinity material comprising a hydrated metal oxide, under conditions wherein a phosphomolecule is capable of binding to the phosphoaffinity material to form a phosphomolecule-phosphoaffinity material complex, and (b) detecting formation of a phosphomolecule-phosphoaffinity material complex, thereby detecting a phosphomolecule in the sample.

Abstract: It is disclosed that the ?v?5 integrin mediates the proliferative signal provided by CD23 to pre-B cells. The region of CD23 which interacts with ?v?5 has been defined, and found to interact with a site on the integrin distinct from that which binds RGD. The invention provides methods for disrupting the interaction between CD23 and ?v?5 and methods of screening for chemical entities capable of disrupting this interaction.

Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.

Abstract: The present invention relates to a selectively soluble polymer capable of binding to a desired biomolecules in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and/or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired biomolecule (protein, polypeptide, etc) and remains capable of binding to that biomolecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed.

Abstract: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.

Abstract: Botanical extracts and derivative compositions are described for activating or inhibiting the formation and development of bacterial biofilms. Gymnemic acids and other associated saponins are isolated from botanical extractions of the Gymnema sylvestre plant and are used to modulate bacterial biofilm virulence, especially biofilms associated with Staphylococcus aureus. Gurmarin, a polypeptide isolated from botanical extractions of the Gymnema sylvestre plant are used to inhibit biofilm formation, especially biofilms associated with Staphylococcus aureus. Methods for isolating gurmarin (as well as other peptides from botanical extracts) are described using isoelectric focusing separation techniques. Various uses for both research and health care concerns are described for the biofilm activators (modulators) and for the biofilm inhibitor.

Abstract: The present invention is a process for separating a target protein (such as a recombinant protein produced in a cell culture) from a mixture containing the target protein and contaminants (such as cell culture contaminants), by contacting the mixture with a hydrophobic adsorbent comprising branched hydrocarbon functional groups in an aqueous salt solution and collecting the unbound flow-through fraction containing the target protein. In one embodiment, the hydrophobic adsorbent may be a branched alkyl functional group. In another embodiment, the branched alkyl functional group has from 3 to 8 carbon atoms. In another embodiment, the branched alkyl functional group is a tertiary carbon atom, such as tert-butyl.

Abstract: Methods for isolation of a synthetic cyclic peptide by spray drying, including spray drying at elevated temperatures, products made by the methods, and synthetic cyclic peptides preparations with defined characteristics, including an essentially amorphous acid addition salt of Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH in the form of a fine powder with a particle diameter of about 2 to about 20 microns.

Abstract: Embodiments of the present invention are directed to articles of manufacture, devices, methods and apparatus for performing liquid chromatography featuring a chromatographic sorbent having one or more pentafluorophenyl groups, wherein said one or more pentafluorophenyl groups are a bonded phase on a sorbent selected from the group comprising silica, organic polymers or hybrid organic silane material and said pentafluorophenyl groups are in a mono-, bi-, and tridentate forms.

Abstract: This invention relates to a process for purifying a polypeptide, a capture tag useful for purifying a polypeptide and a periodate-cleavable amino acid derivative useful for purifying a polypeptide. The polypeptide to be purified comprises a vicinal-amino-thiol, vicinal-amino-hydoxyl, vicinal-diol or vicinal-diamino group. The purification process comprises attaching the polypeptide to a purification matrix by contacting the polypeptide with a purification matrix comprising aldehyde or ketone groups under conditions which favor formation of a heterocyclic ring system, washing the purification matrix, and releasing the polypeptide from the purification matrix.

Abstract: Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.

Abstract: The invention relates to the field of compositions comprising a protein, more specifically to pharmaceutical compositions. More specifically, the invention relates to the detection and/or removal of conformationally altered proteins and/or molecules comprising a cross-? structure from a pharmaceutical composition or any of its constituents comprising a protein. The present invention discloses that unwanted and/or toxic side effects of pharmaceuticals are caused by proteins present in said pharmaceutical and adopting a cross-b structure conformation.

Abstract: Compounds of the general formula (I): in which inter alia Q1 represents —NR1R3, —OR1 or —SR1 and Q2 represents —NR2R4, —OR2 or —SR2, and A represents the point of attachment to a support matrix, are useful as protein binding ligands when (a) at least one of R1, R2, R3 and R4 includes an alkyl group —CnH2n+1 in which n is greater than or equal to 7; (b) at least two of R1, R2, R3 and R4 independently include an alkyl group —CnH2n+1 or a cycloalkyl group —CnH2n?1 in which n is greater than or equal to 4; or (c) at least three of R1, R2, R3 and R4 independently include a C1-12 alkyl group substituted by —NR5R6 or aryl.